Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05571787 · ClinicalTrials.gov registry record · Phase 1

HMPL-523 Food Effect and Proton Pump Inhibitor Study

A Phase 1 study, sponsored by Hutchmed.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT05571787 is a Phase 1 study that has completed, run by Hutchmed. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05571787, a Phase 1 study, has completed, sponsored by Hutchmed.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Interventions

  • DRUG Rabeprazole
  • DRUG HMPL-523

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2022-07-13
Est. Completion 2022-09-22
Phase Phase 1

Sponsor

Hutchmed

17 total trials

What the Registry Record Tells You About NCT05571787

The ClinicalTrials.gov registry entry for NCT05571787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Rabeprazole is the first listed.

NCT05571787 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05571787 about?

NCT05571787 is a clinical study titled "HMPL-523 Food Effect and Proton Pump Inhibitor Study". A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

What is the current status of trial NCT05571787?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2022-07-13. Estimated completion is 2022-09-22.

What interventions are being tested in trial NCT05571787?

The interventions under investigation include: Rabeprazole (DRUG), HMPL-523 (DRUG).

Who is sponsoring clinical trial NCT05571787?

This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.